Management of patients with difficult-to-treat psoriasis in Africa and the Middle East - 22/08/19
Martin Steinhoff, Department of Dermatology and Venereology, and HMC Translational Research Institute, Hamad Medical Corporation, Qatar University and Weill Cornell University – Qatar, Doha, Qatar; Alfred F. Ammoury, Dermatology Division, St. George Hospital UMC, Beirut, Lebanon; Mahira H. El Sayed, Department of Dermatology and Venereology, Ain Shams University, Cairo, Egypt; Reenad Nassier, Pfizer, Jeddah, Saudi Arabia; Nadine Tarcha, Pfizer, Dubai, United Arab Emirates; Mohamed Mounir, Pfizer, Dubai, United Arab Emirates; Fahad M. Al Saif, Department of Dermatology, King Saud University College of Medicine, King Saud Medical City, Riyadh, Saudi Arabia
Le texte complet de cet article est disponible en PDF.| Supported by Pfizer. Mohamed Mouni was an employee of Pfizer at the time of the study. |
Vol 81 - N° 4S1
P. AB91 - octobre 2019 Retour au numéro
Article précédent
- Malignancy rates in patients with moderate to severe psoriasis during treatment with risankizumab: Analysis of pooled clinical trial data
- Managing pitted keratolysis through hyperhidrosis control with topical glycopyrrolate 2%
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?